GZMB and rheumatoid arthritis: The association of glucocorticoid residence and expression of GRβ, which is a dominant negative inhibitor of GRα, have been clinically studied in immune-mediated diseases such as rheumatoid arthritis [37] and ulcerative colitis [38].